ID   SETD2_HUMAN             Reviewed;        2564 AA.
AC   Q9BYW2; O75397; O75405; Q17RW8; Q5BKS9; Q5QGN2; Q69YI5; Q6IN64;
AC   Q6ZN53; Q6ZS25; Q8N3R0; Q8TCN0; Q9C0D1; Q9H696; Q9NZW9;
DT   17-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   10-MAY-2017, entry version 147.
DE   RecName: Full=Histone-lysine N-methyltransferase SETD2;
DE            EC=2.1.1.43;
DE   AltName: Full=HIF-1;
DE   AltName: Full=Huntingtin yeast partner B;
DE   AltName: Full=Huntingtin-interacting protein 1;
DE            Short=HIP-1;
DE   AltName: Full=Huntingtin-interacting protein B;
DE   AltName: Full=Lysine N-methyltransferase 3A;
DE   AltName: Full=SET domain-containing protein 2;
DE            Short=hSET2;
DE   AltName: Full=p231HBP;
GN   Name=SETD2; Synonyms=HIF1, HYPB, KIAA1732, KMT3A, SET2;
GN   ORFNames=HSPC069;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1390.
RC   TISSUE=Brain, and Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 284-2564 (ISOFORM 3),
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 927-1482 (ISOFORMS 1/2/3),
RP   AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2228-2564 (ISOFORM 1).
RC   TISSUE=Adipose tissue;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 368-2564 (ISOFORM 1), DNA-BINDING,
RP   TISSUE SPECIFICITY, AND INTERACTION WITH HTT.
RX   PubMed=11461154; DOI=10.1006/mcne.2001.1004;
RA   Rega S., Stiewe T., Chang D.-I., Pollmeier B., Esche H.,
RA   Bardenheuer W., Marquitan G., Puetzer B.M.;
RT   "Identification of the full-length huntingtin-interacting protein
RT   p231HBP/HYPB as a DNA-binding factor.";
RL   Mol. Cell. Neurosci. 18:68-79(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 388-2564 (ISOFORM 1), AND
RP   VARIANT LEU-1962.
RC   TISSUE=Cerebellum, Duodenum, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 481-2564 (ISOFORM 1), FUNCTION,
RP   AUTOMETHYLATION, MUTAGENESIS OF ARG-1625, AND INTERACTION WITH POLR2A.
RX   PubMed=16118227; DOI=10.1074/jbc.M504012200;
RA   Sun X.-J., Wei J., Wu X.-Y., Hu M., Wang L., Wang H.-H., Zhang Q.-H.,
RA   Chen S.-J., Huang Q.-H., Chen Z.;
RT   "Identification and characterization of a novel human histone H3
RT   lysine 36 specific methyltransferase.";
RL   J. Biol. Chem. 280:35261-35271(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 481-2564 (ISOFORM 2).
RA   Sun X.J., Wei J., Wu X.Y., Hu M., Wang H.H., Zhang Q.H., Huang Q.H.,
RA   Chen Z.;
RT   "Identification of a human histone H3-K36-specific methyltransferase
RT   that is orthologous to Saccharomyces cerevisiae SET2 protein.";
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 650-2564 (ISOFORM 1), AND
RP   VARIANT LEU-1962.
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [9]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1402-2069.
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2378-2564, AND INTERACTION WITH HTT.
RC   TISSUE=Frontal cortex;
RX   PubMed=9700202; DOI=10.1093/hmg/7.9.1463;
RA   Faber P.W., Barnes G.T., Srinidhi J., Chen J., Gusella J.F.,
RA   MacDonald M.E.;
RT   "Huntingtin interacts with a family of WW domain proteins.";
RL   Hum. Mol. Genet. 7:1463-1474(1998).
RN   [12]
RP   INTERACTION WITH HTT.
RX   PubMed=10958656; DOI=10.1093/hmg/9.14.2175;
RA   Passani L.A., Bedford M.T., Faber P.W., McGinnis K.M., Sharp A.H.,
RA   Gusella J.F., Vonsattel J.-P., MacDonald M.E.;
RT   "Huntingtin's WW domain partners in Huntington's disease post-mortem
RT   brain fulfill genetic criteria for direct involvement in Huntington's
RT   disease pathogenesis.";
RL   Hum. Mol. Genet. 9:2175-2182(2000).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   INTERACTION WITH TP53.
RX   PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012;
RA   Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.;
RT   "Histone methyltransferase protein SETD2 interacts with p53 and
RT   selectively regulates its downstream genes.";
RL   Cell. Signal. 20:1671-1678(2008).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH IWS1.
RX   PubMed=19141475; DOI=10.1101/gad.1720008;
RA   Yoh S.M., Lucas J.S., Jones K.A.;
RT   "The Iws1:Spt6:CTD complex controls cotranscriptional mRNA
RT   biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation.";
RL   Genes Dev. 22:3422-3434(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1228, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321; SER-323; SER-624;
RP   SER-754; SER-1228; THR-1872; SER-2080 AND SER-2082, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   INTERACTION WITH HNRNPL.
RX   PubMed=19332550; DOI=10.1074/jbc.M808431200;
RA   Yuan W., Xie J., Long C., Erdjument-Bromage H., Ding X., Zheng Y.,
RA   Tempst P., Chen S., Zhu B., Reinberg D.;
RT   "Heterogeneous nuclear ribonucleoprotein L is a subunit of human
RT   KMT3a/Set2 complex required for H3 Lys-36 trimethylation activity in
RT   vivo.";
RL   J. Biol. Chem. 284:15701-15707(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131; SER-321; SER-323;
RP   SER-708; SER-744 AND SER-754, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   INVOLVEMENT IN RCC.
RX   PubMed=20054297; DOI=10.1038/nature08672;
RA   Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A.,
RA   Davies H., Edkins S., Hardy C., Latimer C., Teague J., Andrews J.,
RA   Barthorpe S., Beare D., Buck G., Campbell P.J., Forbes S., Jia M.,
RA   Jones D., Knott H., Kok C.Y., Lau K.W., Leroy C., Lin M.L.,
RA   McBride D.J., Maddison M., Maguire S., McLay K., Menzies A.,
RA   Mironenko T., Mulderrig L., Mudie L., O'Meara S., Pleasance E.,
RA   Rajasingham A., Shepherd R., Smith R., Stebbings L., Stephens P.,
RA   Tang G., Tarpey P.S., Turrell K., Dykema K.J., Khoo S.K., Petillo D.,
RA   Wondergem B., Anema J., Kahnoski R.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Systematic sequencing of renal carcinoma reveals inactivation of
RT   histone modifying genes.";
RL   Nature 463:360-363(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321; SER-323; SER-624
RP   AND THR-1872, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   FUNCTION.
RX   PubMed=21792193; DOI=10.1038/nsmb.2123;
RA   de Almeida S.F., Grosso A.R., Koch F., Fenouil R., Carvalho S.,
RA   Andrade J., Levezinho H., Gut M., Eick D., Gut I., Andrau J.C.,
RA   Ferrier P., Carmo-Fonseca M.;
RT   "Splicing enhances recruitment of methyltransferase HYPB/Setd2 and
RT   methylation of histone H3 Lys36.";
RL   Nat. Struct. Mol. Biol. 18:977-983(2011).
RN   [24]
RP   FUNCTION.
RX   PubMed=21526191; DOI=10.1371/journal.pone.0018844;
RA   Hahn M.A., Wu X., Li A.X., Hahn T., Pfeifer G.P.;
RT   "Relationship between gene body DNA methylation and intragenic H3K9me3
RT   and H3K36me3 chromatin marks.";
RL   PLoS ONE 6:E18844-E18844(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321; SER-323; SER-624;
RP   SER-754 AND SER-2082, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   INVOLVEMENT IN LLS.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B.,
RA   Phelps I.G., Carvill G., Kumar A., Lee C., Ankenman K., Munson J.,
RA   Hiatt J.B., Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P.,
RA   Martin B.K., Borenstein E., Nickerson D.A., Mefford H.C., Doherty D.,
RA   Akey J.M., Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [27]
RP   FUNCTION, INVOLVEMENT IN RCC, VARIANTS ASP-1733 AND PRO-1769, AND
RP   CHARACTERIZATION OF VARIANTS ASP-1733 AND PRO-1769.
RX   PubMed=23622243; DOI=10.1016/j.cell.2013.03.025;
RA   Li F., Mao G., Tong D., Huang J., Gu L., Yang W., Li G.M.;
RT   "The histone mark H3K36me3 regulates human DNA mismatch repair through
RT   its interaction with MutSalpha.";
RL   Cell 153:590-600(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131; SER-344; SER-422;
RP   SER-532; SER-614; SER-624; THR-626; SER-744; SER-754; SER-1098;
RP   SER-1228; SER-1696; THR-1853; THR-1872; SER-1888; SER-1952; SER-2080
RP   AND SER-2082, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   INVOLVEMENT IN RCC.
RX   PubMed=23792563; DOI=10.1038/nature12222;
RA   Creighton C.J., Morgan M., Gunaratne P.H., Wheeler D.A., Gibbs R.A.,
RA   Gordon Robertson A., Chu A., Beroukhim R., Cibulskis K.,
RA   Signoretti S., Vandin Hsin-Ta Wu F., Raphael B.J., Verhaak R.G.,
RA   Tamboli P., Torres-Garcia W., Akbani R., Weinstein J.N., Reuter V.,
RA   Hsieh J.J., Rose Brannon A., Ari Hakimi A., Jacobsen A., Ciriello G.,
RA   Reva B., Ricketts C.J., Marston Linehan W., Stuart J.M.,
RA   Kimryn Rathmell W., Shen H., Laird P.W., Muzny D., Davis C.,
RA   Morgan M., Xi L., Chang K., Kakkar N., Trevino L.R., Benton S.,
RA   Reid J.G., Morton D., Doddapaneni H., Han Y., Lewis L., Dinh H.,
RA   Kovar C., Zhu Y., Santibanez J., Wang M., Hale W., Kalra D.,
RA   Creighton C.J., Wheeler D.A., Gibbs R.A., Getz G., Cibulskis K.,
RA   Lawrence M.S., Sougnez C., Carter S.L., Sivachenko A.,
RA   Lichtenstein L., Stewart C., Voet D., Fisher S., Gabriel S.B.,
RA   Lander E., Beroukhim R., Schumacher S.E., Tabak B., Saksena G.,
RA   Onofrio R.C., Carter S.L., Cherniack A.D., Gentry J., Ardlie K.,
RA   Sougnez C., Getz G., Gabriel S.B., Meyerson M., Gordon Robertson A.,
RA   Chu A., Chun H.J., Mungall A.J., Sipahimalani P., Stoll D., Ally A.,
RA   Balasundaram M., Butterfield Y.S., Carlsen R., Carter C., Chuah E.,
RA   Coope R.J., Dhalla N., Gorski S., Guin R., Hirst C., Hirst M.,
RA   Holt R.A., Lebovitz C., Lee D., Li H.I., Mayo M., Moore R.A.,
RA   Pleasance E., Plettner P., Schein J.E., Shafiei A., Slobodan J.R.,
RA   Tam A., Thiessen N., Varhol R.J., Wye N., Zhao Y., Birol I.,
RA   Jones S.J., Marra M.A., Auman J.T., Tan D., Jones C.D., Hoadley K.A.,
RA   Mieczkowski P.A., Mose L.E., Jefferys S.R., Topal M.D., Liquori C.,
RA   Turman Y.J., Shi Y., Waring S., Buda E., Walsh J., Wu J.,
RA   Bodenheimer T., Hoyle A.P., Simons J.V., Soloway M.G., Balu S.,
RA   Parker J.S., Neil Hayes D., Perou C.M., Kucherlapati R., Park P.,
RA   Shen H., Triche T. Jr., Weisenberger D.J., Lai P.H., Bootwalla M.S.,
RA   Maglinte D.T., Mahurkar S., Berman B.P., Van Den Berg D.J., Cope L.,
RA   Baylin S.B., Laird P.W., Creighton C.J., Wheeler D.A., Getz G.,
RA   Noble M.S., Dicara D., Zhang H., Cho J., Heiman D.I., Gehlenborg N.,
RA   Voet D., Mallard W., Lin P., Frazer S., Stojanov P., Liu Y., Zhou L.,
RA   Kim J., Lawrence M.S., Chin L., Vandin F., Wu H.T., Raphael B.J.,
RA   Benz C., Yau C., Reynolds S.M., Shmulevich I., Verhaak R.G.,
RA   Torres-Garcia W., Vegesna R., Kim H., Zhang W., Cogdell D.,
RA   Jonasch E., Ding Z., Lu Y., Akbani R., Zhang N., Unruh A.K.,
RA   Casasent T.D., Wakefield C., Tsavachidou D., Chin L., Mills G.B.,
RA   Weinstein J.N., Jacobsen A., Rose Brannon A., Ciriello G., Schultz N.,
RA   Ari Hakimi A., Reva B., Antipin Y., Gao J., Cerami E., Gross B.,
RA   Arman Aksoy B., Sinha R., Weinhold N., Onur Sumer S., Taylor B.S.,
RA   Shen R., Ostrovnaya I., Hsieh J.J., Berger M.F., Ladanyi M.,
RA   Sander C., Fei S.S., Stout A., Spellman P.T., Rubin D.L., Liu T.T.,
RA   Stuart J.M., Ng S., Paull E.O., Carlin D., Goldstein T., Waltman P.,
RA   Ellrott K., Zhu J., Haussler D., Gunaratne P.H., Xiao W., Shelton C.,
RA   Gardner J., Penny R., Sherman M., Mallery D., Morris S.,
RA   Paulauskis J., Burnett K., Shelton T., Signoretti S., Kaelin W.G.,
RA   Choueiri T., Atkins M.B., Penny R., Burnett K., Mallery D., Curley E.,
RA   Tickoo S., Reuter V., Kimryn Rathmell W., Thorne L., Boice L.,
RA   Huang M., Fisher J.C., Marston Linehan W., Vocke C.D., Peterson J.,
RA   Worrell R., Merino M.J., Schmidt L.S., Tamboli P., Czerniak B.A.,
RA   Aldape K.D., Wood C.G., Boyd J., Weaver J., Iacocca M.V., Petrelli N.,
RA   Witkin G., Brown J., Czerwinski C., Huelsenbeck-Dill L., Rabeno B.,
RA   Myers J., Morrison C., Bergsten J., Eckman J., Harr J., Smith C.,
RA   Tucker K., Anne Zach L., Bshara W., Gaudioso C., Morrison C., Dhir R.,
RA   Maranchie J., Nelson J., Parwani A., Potapova O., Fedosenko K.,
RA   Cheville J.C., Houston Thompson R., Signoretti S., Kaelin W.G.,
RA   Atkins M.B., Tickoo S., Reuter V., Marston Linehan W., Vocke C.D.,
RA   Peterson J., Merino M.J., Schmidt L.S., Tamboli P., Mosquera J.M.,
RA   Rubin M.A., Blute M.L., Kimryn Rathmell W., Pihl T., Jensen M.,
RA   Sfeir R., Kahn A., Chu A., Kothiyal P., Snyder E., Pontius J.,
RA   Ayala B., Backus M., Walton J., Baboud J., Berton D., Nicholls M.,
RA   Srinivasan D., Raman R., Girshik S., Kigonya P., Alonso S.,
RA   Sanbhadti R., Barletta S., Pot D., Sheth M., Demchok J.A.,
RA   Davidsen T., Wang Z., Yang L., Tarnuzzer R.W., Zhang J., Eley G.,
RA   Ferguson M.L., Mills Shaw K.R., Guyer M.S., Ozenberger B.A.,
RA   Sofia H.J.;
RT   "Comprehensive molecular characterization of clear cell renal cell
RT   carcinoma.";
RL   Nature 499:43-49(2013).
RN   [30]
RP   FUNCTION.
RX   PubMed=23325844; DOI=10.1093/nar/gks1472;
RA   Carvalho S., Raposo A.C., Martins F.B., Grosso A.R., Sridhara S.C.,
RA   Rino J., Carmo-Fonseca M., de Almeida S.F.;
RT   "Histone methyltransferase SETD2 coordinates FACT recruitment with
RT   nucleosome dynamics during transcription.";
RL   Nucleic Acids Res. 41:2881-2893(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321; SER-614 AND
RP   THR-1853, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   INVOLVEMENT IN LLS.
RX   PubMed=26084711; DOI=10.1007/s10803-015-2484-8;
RA   Lumish H.S., Wynn J., Devinsky O., Chung W.K.;
RT   "SETD2 mutation in a child with autism, intellectual disabilities and
RT   epilepsy.";
RL   J. Autism Dev. Disord. 45:3764-3770(2015).
RN   [33]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-637, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [34]
RP   FUNCTION AS ALPHA-TUBULIN METHYLTRANSFERASE, AND INTERACTION WITH
RP   TUBA1A.
RX   PubMed=27518565; DOI=10.1016/j.cell.2016.07.005;
RA   Park I.Y., Powell R.T., Tripathi D.N., Dere R., Ho T.H., Blasius T.L.,
RA   Chiang Y.C., Davis I.J., Fahey C.C., Hacker K.E., Verhey K.J.,
RA   Bedford M.T., Jonasch E., Rathmell W.K., Walker C.L.;
RT   "Dual chromatin and cytoskeletal remodeling by SETD2.";
RL   Cell 166:950-962(2016).
RN   [35]
RP   POSSIBLE INVOLVEMENT IN LLS.
RX   PubMed=27317772; DOI=10.1136/jmedgenet-2015-103638;
RA   Tlemsani C., Luscan A., Leulliot N., Bieth E., Afenjar A., Baujat G.,
RA   Doco-Fenzy M., Goldenberg A., Lacombe D., Lambert L., Odent S.,
RA   Pasche J., Sigaudy S., Buffet A., Violle-Poirsier C.,
RA   Briand-Suleau A., Laurendeau I., Chin M., Saugier-Veber P., Vidaud D.,
RA   Cormier-Daire V., Vidaud M., Pasmant E., Burglen L.;
RT   "SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort.";
RL   J. Med. Genet. 0:0-0(2016).
RN   [36]
RP   STRUCTURE BY NMR OF 2457-2564, INTERACTION WITH POLR2A, AND
RP   MUTAGENESIS OF ARG-2475; LYS-2476; GLN-2480; PHE-2481; VAL-2483;
RP   PHE-2505; LYS-2506; ARG-2510; HIS-2514; GLY-2515; GLU-2528 AND
RP   GLU-2531.
RX   PubMed=16314571; DOI=10.1073/pnas.0506350102;
RA   Li M., Phatnani H.P., Guan Z., Sage H., Greenleaf A.L., Zhou P.;
RT   "Solution structure of the Set2-Rpb1 interacting domain of human Set2
RT   and its interaction with the hyperphosphorylated C-terminal domain of
RT   Rpb1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:17636-17641(2005).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.99 ANGSTROMS) OF 1434-1711 IN COMPLEX WITH
RP   S-ADENOSYL-L-METHIONINE OR N-PROPYL SINEFUNGIN, FUNCTION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, ENZYME REGULATION,
RP   AND MUTAGENESIS OF PHE-1668; GLN-1669; ARG-1670 AND TYR-1671.
RX   PubMed=23043551; DOI=10.1021/ja307060p;
RA   Zheng W., Ibanez G., Wu H., Blum G., Zeng H., Dong A., Li F.,
RA   Hajian T., Allali-Hassani A., Amaya M.F., Siarheyeva A., Yu W.,
RA   Brown P.J., Schapira M., Vedadi M., Min J., Luo M.;
RT   "Sinefungin derivatives as inhibitors and structure probes of protein
RT   lysine methyltransferase SETD2.";
RL   J. Am. Chem. Soc. 134:18004-18014(2012).
RN   [38]
RP   VARIANT LLS TRP-1815.
RX   PubMed=24852293; DOI=10.1136/jmedgenet-2014-102402;
RA   Luscan A., Laurendeau I., Malan V., Francannet C., Odent S.,
RA   Giuliano F., Lacombe D., Touraine R., Vidaud M., Pasmant E.,
RA   Cormier-Daire V.;
RT   "Mutations in SETD2 cause a novel overgrowth condition.";
RL   J. Med. Genet. 51:512-517(2014).
CC   -!- FUNCTION: Histone methyltransferase that specifically
CC       trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated
CC       'Lys-36' (H3K36me2) as substrate. Represents the main enzyme
CC       generating H3K36me3, a specific tag for epigenetic transcriptional
CC       activation. Plays a role in chromatin structure modulation during
CC       elongation by coordinating recruitment of the FACT complex and by
CC       interacting with hyperphosphorylated POLR2A. Acts as a key
CC       regulator of DNA mismatch repair in G1 and early S phase by
CC       generating H3K36me3, a mark required to recruit MSH6 subunit of
CC       the MutS alpha complex: early recruitment of the MutS alpha
CC       complex to chromatin to be replicated allows a quick
CC       identification of mismatch DNA to initiate the mismatch repair
CC       reaction. H3K36me3 also plays an essential role in the maintenance
CC       of a heterochromatic state, by recruiting DNA methyltransferase
CC       DNMT3A. H3K36me3 is also enhanced in intron-containing genes,
CC       suggesting that SETD2 recruitment is enhanced by splicing and that
CC       splicing is coupled to recruitment of elongating RNA polymerase.
CC       Required during angiogenesis. Recruited to the promoters of
CC       adenovirus 12 E1A gene in case of infection, possibly leading to
CC       regulate its expression. Trimethylates 'Lys-40' of alpha-tubulins
CC       such as TUBA1B (alpha-TubK40me3) (PubMed:27518565). Alpha-
CC       TubK40me3 is required for normal mitosis and cytokinesis and is
CC       proposed to be a specific tag in cytoskeletal remodeling
CC       (PubMed:27518565). {ECO:0000269|PubMed:16118227,
CC       ECO:0000269|PubMed:19141475, ECO:0000269|PubMed:21526191,
CC       ECO:0000269|PubMed:21792193, ECO:0000269|PubMed:23043551,
CC       ECO:0000269|PubMed:23325844, ECO:0000269|PubMed:23622243,
CC       ECO:0000269|PubMed:27518565}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000269|PubMed:23043551}.
CC   -!- ENZYME REGULATION: Specifically inhibited by sinefungin
CC       derivatives. N-propyl sinefungin (Pr-SNF) interacts preferentially
CC       with SETD2. {ECO:0000269|PubMed:23043551}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.21 uM for S-adenosyl-L-methionine
CC         {ECO:0000269|PubMed:23043551};
CC         KM=0.42 uM for histone H3 {ECO:0000269|PubMed:23043551};
CC         Note=Kcat is 0.14 min(-1).;
CC   -!- SUBUNIT: Specifically interacts with hyperphosphorylated C-
CC       terminal domain (CTD) of RNA polymerase II large subunit (POLR2A):
CC       binds to CTD heptad repeats doubly phosphorylated on 'Ser-2' and
CC       'Ser-5' of each heptad. Interacts with HTT and IWS1. Interacts
CC       with p53/TP53; leading to regulate p53/TP53 target genes.
CC       Component of a complex with HNRNPL. Interacts with TUBA1A; the
CC       interaction is independent on alpha-tubulin acetylation on 'Lys-
CC       40'. {ECO:0000269|PubMed:10958656, ECO:0000269|PubMed:11461154,
CC       ECO:0000269|PubMed:16118227, ECO:0000269|PubMed:16314571,
CC       ECO:0000269|PubMed:18585004, ECO:0000269|PubMed:19141475,
CC       ECO:0000269|PubMed:19332550, ECO:0000269|PubMed:23043551,
CC       ECO:0000269|PubMed:9700202}.
CC   -!- INTERACTION:
CC       P42858:HTT; NbExp=4; IntAct=EBI-945869, EBI-466029;
CC       P84022:SMAD3; NbExp=2; IntAct=EBI-945869, EBI-347161;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}. Chromosome
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9BYW2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BYW2-2; Sequence=VSP_020915;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9BYW2-3; Sequence=VSP_020914;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:11461154}.
CC   -!- DOMAIN: The low charge region mediates the transcriptional
CC       activation activity. {ECO:0000269|PubMed:16118227}.
CC   -!- PTM: May be automethylated.
CC   -!- DISEASE: Renal cell carcinoma (RCC) [MIM:144700]: Renal cell
CC       carcinoma is a heterogeneous group of sporadic or hereditary
CC       carcinoma derived from cells of the proximal renal tubular
CC       epithelium. It is subclassified into clear cell renal carcinoma
CC       (non-papillary carcinoma), papillary renal cell carcinoma,
CC       chromophobe renal cell carcinoma, collecting duct carcinoma with
CC       medullary carcinoma of the kidney, and unclassified renal cell
CC       carcinoma. Clear cell renal cell carcinoma is the most common
CC       subtype. {ECO:0000269|PubMed:20054297,
CC       ECO:0000269|PubMed:23622243, ECO:0000269|PubMed:23792563}.
CC       Note=The disease may be caused by mutations affecting the gene
CC       represented in this entry. Defects of SETD2 are associated with
CC       loss of DNA methylation at non-promoter regions (PubMed:23792563).
CC       {ECO:0000269|PubMed:23792563}.
CC   -!- DISEASE: Luscan-Lumish syndrome (LLS) [MIM:616831]: An autosomal
CC       dominant syndrome with a variable phenotype. Clinical features
CC       include macrocephaly, distinctive facial appearance, postnatal
CC       overgrowth, various degrees of learning difficulties, autism
CC       spectrum disorder, and intellectual disability.
CC       {ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:24852293,
CC       ECO:0000269|PubMed:26084711, ECO:0000269|PubMed:27317772}.
CC       Note=The disease may be caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding
CC       methyltransferase superfamily. Histone-lysine methyltransferase
CC       family. SET2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF29041.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC       Sequence=AAH72440.1; Type=Erroneous termination; Positions=463; Note=Translated as Glu.; Evidence={ECO:0000305};
CC       Sequence=AAI17163.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAI17165.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAT77612.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAT77613.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15367.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15367.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAC87131.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAC28349.1; Type=Erroneous termination; Positions=385; Note=Translated as Arg.; Evidence={ECO:0000305};
CC       Sequence=CAD38601.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC094020; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC127430; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK026125; BAB15367.1; ALT_SEQ; mRNA.
DR   EMBL; AK127782; BAC87131.1; ALT_INIT; mRNA.
DR   EMBL; AK131371; BAD18522.1; -; mRNA.
DR   EMBL; AL713692; CAD28492.1; -; mRNA.
DR   EMBL; AL831959; CAD38601.2; ALT_INIT; mRNA.
DR   EMBL; AL833394; CAH10589.1; -; mRNA.
DR   EMBL; AJ238403; CAC28349.1; ALT_SEQ; mRNA.
DR   EMBL; BC072440; AAH72440.1; ALT_SEQ; mRNA.
DR   EMBL; BC090954; AAH90954.1; -; mRNA.
DR   EMBL; BC117162; AAI17163.1; ALT_INIT; mRNA.
DR   EMBL; BC117164; AAI17165.1; ALT_INIT; mRNA.
DR   EMBL; AY576987; AAT77612.1; ALT_INIT; mRNA.
DR   EMBL; AY576988; AAT77613.1; ALT_INIT; mRNA.
DR   EMBL; AB051519; BAB21823.2; -; mRNA.
DR   EMBL; AF161554; AAF29041.1; ALT_FRAME; mRNA.
DR   EMBL; AF049103; AAC26194.1; -; mRNA.
DR   EMBL; AF049610; AAC26846.1; -; mRNA.
DR   CCDS; CCDS2749.2; -. [Q9BYW2-1]
DR   RefSeq; NP_054878.5; NM_014159.6. [Q9BYW2-1]
DR   UniGene; Hs.517941; -.
DR   PDB; 2A7O; NMR; -; A=2457-2564.
DR   PDB; 2MDC; NMR; -; A=2385-2430.
DR   PDB; 2MDI; NMR; -; A=2377-2430.
DR   PDB; 2MDJ; NMR; -; A=2377-2430.
DR   PDB; 4FMU; X-ray; 2.10 A; A=1434-1711.
DR   PDB; 4H12; X-ray; 1.99 A; A=1434-1711.
DR   PDB; 5JJY; X-ray; 2.05 A; A=1434-1711.
DR   PDB; 5JLB; X-ray; 1.50 A; A=1434-1711.
DR   PDB; 5JLE; X-ray; 2.40 A; A=1434-1711.
DR   PDB; 5LSS; X-ray; 1.79 A; A=1433-1711.
DR   PDB; 5LSX; X-ray; 2.90 A; A=1433-1711.
DR   PDB; 5LSY; X-ray; 1.62 A; A=1433-1711.
DR   PDB; 5LSZ; X-ray; 1.62 A; A=1433-1711.
DR   PDB; 5LT6; X-ray; 2.05 A; A/B=1433-1711.
DR   PDB; 5LT7; X-ray; 1.51 A; A=1433-1711.
DR   PDB; 5LT8; X-ray; 1.57 A; A=1433-1711.
DR   PDB; 5V21; X-ray; 2.42 A; A=1435-1711.
DR   PDB; 5V22; X-ray; 2.40 A; A=1435-1711.
DR   PDBsum; 2A7O; -.
DR   PDBsum; 2MDC; -.
DR   PDBsum; 2MDI; -.
DR   PDBsum; 2MDJ; -.
DR   PDBsum; 4FMU; -.
DR   PDBsum; 4H12; -.
DR   PDBsum; 5JJY; -.
DR   PDBsum; 5JLB; -.
DR   PDBsum; 5JLE; -.
DR   PDBsum; 5LSS; -.
DR   PDBsum; 5LSX; -.
DR   PDBsum; 5LSY; -.
DR   PDBsum; 5LSZ; -.
DR   PDBsum; 5LT6; -.
DR   PDBsum; 5LT7; -.
DR   PDBsum; 5LT8; -.
DR   PDBsum; 5V21; -.
DR   PDBsum; 5V22; -.
DR   ProteinModelPortal; Q9BYW2; -.
DR   SMR; Q9BYW2; -.
DR   BioGrid; 118845; 36.
DR   IntAct; Q9BYW2; 15.
DR   MINT; MINT-1537591; -.
DR   STRING; 9606.ENSP00000386759; -.
DR   BindingDB; Q9BYW2; -.
DR   ChEMBL; CHEMBL3108647; -.
DR   iPTMnet; Q9BYW2; -.
DR   PhosphoSitePlus; Q9BYW2; -.
DR   BioMuta; SETD2; -.
DR   DMDM; 296452963; -.
DR   OGP; Q9BYW2; -.
DR   EPD; Q9BYW2; -.
DR   MaxQB; Q9BYW2; -.
DR   PaxDb; Q9BYW2; -.
DR   PeptideAtlas; Q9BYW2; -.
DR   PRIDE; Q9BYW2; -.
DR   Ensembl; ENST00000409792; ENSP00000386759; ENSG00000181555. [Q9BYW2-1]
DR   GeneID; 29072; -.
DR   KEGG; hsa:29072; -.
DR   UCSC; uc003cqs.4; human. [Q9BYW2-1]
DR   CTD; 29072; -.
DR   DisGeNET; 29072; -.
DR   GeneCards; SETD2; -.
DR   H-InvDB; HIX0021942; -.
DR   H-InvDB; HIX0163343; -.
DR   HGNC; HGNC:18420; SETD2.
DR   HPA; HPA042451; -.
DR   MalaCards; SETD2; -.
DR   MIM; 144700; phenotype.
DR   MIM; 612778; gene.
DR   MIM; 616831; phenotype.
DR   neXtProt; NX_Q9BYW2; -.
DR   OpenTargets; ENSG00000181555; -.
DR   Orphanet; 821; Sotos syndrome.
DR   PharmGKB; PA143485612; -.
DR   eggNOG; KOG4442; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   GeneTree; ENSGT00780000121845; -.
DR   HOVERGEN; HBG093939; -.
DR   InParanoid; Q9BYW2; -.
DR   KO; K11423; -.
DR   OMA; FIGHDSH; -.
DR   OrthoDB; EOG091G040P; -.
DR   PhylomeDB; Q9BYW2; -.
DR   TreeFam; TF106477; -.
DR   BRENDA; 2.1.1.43; 2681.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   SignaLink; Q9BYW2; -.
DR   SIGNOR; Q9BYW2; -.
DR   ChiTaRS; SETD2; human.
DR   EvolutionaryTrace; Q9BYW2; -.
DR   GeneWiki; SETD2; -.
DR   GenomeRNAi; 29072; -.
DR   PRO; PR:Q9BYW2; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000181555; -.
DR   CleanEx; HS_SETD2; -.
DR   ExpressionAtlas; Q9BYW2; baseline and differential.
DR   Genevisible; Q9BYW2; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0046975; F:histone methyltransferase activity (H3-K36 specific); IDA:HGNC.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0035441; P:cell migration involved in vasculogenesis; IEA:Ensembl.
DR   GO; GO:0060977; P:coronary vasculature morphogenesis; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl.
DR   GO; GO:0060669; P:embryonic placenta morphogenesis; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0097676; P:histone H3-K36 dimethylation; IDA:HGNC.
DR   GO; GO:0097198; P:histone H3-K36 trimethylation; IDA:UniProtKB.
DR   GO; GO:0048332; P:mesoderm morphogenesis; IEA:Ensembl.
DR   GO; GO:0006298; P:mismatch repair; IMP:UniProtKB.
DR   GO; GO:0001763; P:morphogenesis of a branching structure; IEA:Ensembl.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0034728; P:nucleosome organization; IMP:UniProtKB.
DR   GO; GO:0060039; P:pericardium development; IEA:Ensembl.
DR   GO; GO:0010793; P:regulation of mRNA export from nucleus; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0048864; P:stem cell development; IEA:Ensembl.
DR   GO; GO:0006368; P:transcription elongation from RNA polymerase II promoter; IMP:UniProtKB.
DR   InterPro; IPR006560; AWS_dom.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR013257; SRI.
DR   InterPro; IPR001202; WW_dom.
DR   Pfam; PF00856; SET; 1.
DR   Pfam; PF08236; SRI; 1.
DR   Pfam; PF00397; WW; 1.
DR   SMART; SM00570; AWS; 1.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00317; SET; 1.
DR   SMART; SM00456; WW; 1.
DR   SUPFAM; SSF51045; SSF51045; 1.
DR   PROSITE; PS51215; AWS; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 1.
DR   PROSITE; PS50020; WW_DOMAIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing;
KW   Autism spectrum disorder; Chromatin regulator; Chromosome;
KW   Coiled coil; Complete proteome; Disease mutation; Isopeptide bond;
KW   Mental retardation; Methyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; S-adenosyl-L-methionine;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1   2564       Histone-lysine N-methyltransferase SETD2.
FT                                /FTId=PRO_0000252367.
FT   DOMAIN     1494   1548       AWS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00562}.
FT   DOMAIN     1550   1667       SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00190}.
FT   DOMAIN     1674   1690       Post-SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00155}.
FT   DOMAIN     2389   2422       WW. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   REGION     1418   1714       Interaction with TUBA1A.
FT                                {ECO:0000269|PubMed:27518565}.
FT   REGION     1560   1562       Inhibitor binding.
FT   REGION     1560   1562       S-adenosyl-L-methionine binding.
FT   REGION     1603   1605       Inhibitor binding.
FT   REGION     1603   1605       S-adenosyl-L-methionine binding.
FT   REGION     1628   1629       Inhibitor binding.
FT   REGION     1628   1629       S-adenosyl-L-methionine binding.
FT   REGION     2137   2366       Low charge region.
FT   REGION     2457   2564       Interaction with POLR2A.
FT   COILED     2117   2146       {ECO:0000255}.
FT   COMPBIAS    166    247       Pro-rich.
FT   COMPBIAS    385    456       Arg-rich.
FT   COMPBIAS   2149   2232       Pro-rich.
FT   COMPBIAS   2266   2365       Gln-rich.
FT   BINDING    1625   1625       Inhibitor.
FT   BINDING    1676   1676       Inhibitor; alternate.
FT   BINDING    1676   1676       S-adenosyl-L-methionine; alternate.
FT   BINDING    1679   1679       Inhibitor; via amide nitrogen; alternate.
FT   BINDING    1679   1679       S-adenosyl-L-methionine; via amide
FT                                nitrogen; alternate.
FT   MOD_RES     131    131       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     321    321       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     323    323       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     344    344       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     422    422       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     532    532       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     614    614       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     624    624       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     626    626       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     698    698       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES     708    708       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     744    744       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     754    754       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1098   1098       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1228   1228       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1413   1413       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    1415   1415       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    1417   1417       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    1696   1696       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1844   1844       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    1845   1845       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    1853   1853       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1872   1872       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1888   1888       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1952   1952       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1980   1980       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    1988   1988       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    1995   1995       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:E9Q5F9}.
FT   MOD_RES    2080   2080       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2082   2082       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    637    637       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297}.
FT   VAR_SEQ    1573   2564       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_020914.
FT   VAR_SEQ    1715   2564       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_020915.
FT   VARIANT     768    768       V -> L (in dbSNP:rs9311404).
FT                                /FTId=VAR_027839.
FT   VARIANT     902    902       E -> Q (in dbSNP:rs58906143).
FT                                /FTId=VAR_061216.
FT   VARIANT    1733   1733       N -> D (in RCC cell line; defects in
FT                                recruitment of the MutS alpha complex).
FT                                {ECO:0000269|PubMed:23622243}.
FT                                /FTId=VAR_069812.
FT   VARIANT    1769   1769       S -> P (in RCC cell line; defects in
FT                                recruitment of the MutS alpha complex).
FT                                {ECO:0000269|PubMed:23622243}.
FT                                /FTId=VAR_069813.
FT   VARIANT    1815   1815       L -> W (in LLS; unknown pathological
FT                                significance; dbSNP:rs869025570).
FT                                {ECO:0000269|PubMed:24852293}.
FT                                /FTId=VAR_076536.
FT   VARIANT    1868   1868       A -> D (in dbSNP:rs11721074).
FT                                /FTId=VAR_027840.
FT   VARIANT    1962   1962       P -> L (in dbSNP:rs4082155).
FT                                {ECO:0000269|PubMed:11214970,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_027841.
FT   MUTAGEN    1625   1625       R->H: Loss of methyltransferase activity.
FT                                {ECO:0000269|PubMed:16118227}.
FT   MUTAGEN    1668   1668       F->A: Loss of methyltransferase activity.
FT                                {ECO:0000269|PubMed:23043551}.
FT   MUTAGEN    1669   1669       Q->A: Loss of methyltransferase activity.
FT                                {ECO:0000269|PubMed:23043551}.
FT   MUTAGEN    1670   1670       R->A,V,L,I,F: Impaired methyltransferase
FT                                activity. {ECO:0000269|PubMed:23043551}.
FT   MUTAGEN    1670   1670       R->P,W,K,Q: Loss of methyltransferase
FT                                activity. {ECO:0000269|PubMed:23043551}.
FT   MUTAGEN    1671   1671       Y->A: Loss of methyltransferase activity.
FT                                {ECO:0000269|PubMed:23043551}.
FT   MUTAGEN    2475   2475       R->A: Does not affect interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2476   2476       K->A: Does not affect interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2480   2480       Q->A: Does not affect interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2481   2481       F->A: Does not affect interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2483   2483       V->A: Impairs interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2505   2505       F->L: Impairs interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2506   2506       K->A: Impairs interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2510   2510       R->A: Impairs interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2514   2514       H->A: Impairs interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2515   2515       G->A,T: Does not affect interaction with
FT                                hyperphosphorylated POLR2A.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2528   2528       E->A: Increases interaction with
FT                                hyperphosphorylated POLR2A; when
FT                                associated with A-2531.
FT                                {ECO:0000269|PubMed:16314571}.
FT   MUTAGEN    2531   2531       E->A: Increases interaction with
FT                                hyperphosphorylated POLR2A; when
FT                                associated with A-2528.
FT                                {ECO:0000269|PubMed:16314571}.
FT   CONFLICT    448    448       R -> Q (in Ref. 2; BAD18522).
FT                                {ECO:0000305}.
FT   CONFLICT    455    455       A -> V (in Ref. 3; CAD38601).
FT                                {ECO:0000305}.
FT   CONFLICT    912    912       L -> P (in Ref. 2; BAB15367).
FT                                {ECO:0000305}.
FT   CONFLICT    964    964       E -> K (in Ref. 4; CAC28349, 6; AAT77612
FT                                and 7; AAT77613). {ECO:0000305}.
FT   CONFLICT   1080   1080       M -> I (in Ref. 2; BAC87131).
FT                                {ECO:0000305}.
FT   CONFLICT   1080   1080       M -> T (in Ref. 3; CAD38601).
FT                                {ECO:0000305}.
FT   CONFLICT   1212   1212       V -> F (in Ref. 2; BAD18522).
FT                                {ECO:0000305}.
FT   CONFLICT   1269   1269       T -> A (in Ref. 4; CAC28349, 6; AAT77612
FT                                and 7; AAT77613). {ECO:0000305}.
FT   CONFLICT   1338   1338       E -> G (in Ref. 2; BAB15367).
FT                                {ECO:0000305}.
FT   CONFLICT   1498   1498       Q -> R (in Ref. 3; CAD38601).
FT                                {ECO:0000305}.
FT   CONFLICT   1706   1706       K -> N (in Ref. 10; AAF29041).
FT                                {ECO:0000305}.
FT   CONFLICT   1736   1736       L -> P (in Ref. 4; CAC28349 and 6;
FT                                AAT77612). {ECO:0000305}.
FT   STRAND     1448   1450       {ECO:0000244|PDB:5JLB}.
FT   HELIX      1451   1455       {ECO:0000244|PDB:5JLB}.
FT   HELIX      1457   1465       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1480   1483       {ECO:0000244|PDB:5JLB}.
FT   HELIX      1506   1511       {ECO:0000244|PDB:5JLB}.
FT   HELIX      1521   1524       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1531   1533       {ECO:0000244|PDB:5LSX}.
FT   HELIX      1536   1538       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1539   1541       {ECO:0000244|PDB:5JLE}.
FT   TURN       1543   1547       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1552   1556       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1558   1560       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1562   1568       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1575   1578       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1582   1584       {ECO:0000244|PDB:5JLB}.
FT   HELIX      1586   1598       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1606   1610       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1613   1616       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1618   1621       {ECO:0000244|PDB:5JLB}.
FT   HELIX      1623   1626       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1634   1642       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1645   1654       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1661   1664       {ECO:0000244|PDB:5JLB}.
FT   HELIX      1667   1670       {ECO:0000244|PDB:5LT7}.
FT   STRAND     1672   1674       {ECO:0000244|PDB:5JLB}.
FT   STRAND     1675   1677       {ECO:0000244|PDB:5LT7}.
FT   STRAND     1687   1691       {ECO:0000244|PDB:5LT7}.
FT   HELIX      1697   1700       {ECO:0000244|PDB:5JLB}.
FT   STRAND     2377   2379       {ECO:0000244|PDB:2MDJ}.
FT   HELIX      2386   2388       {ECO:0000244|PDB:2MDI}.
FT   STRAND     2392   2399       {ECO:0000244|PDB:2MDC}.
FT   TURN       2401   2403       {ECO:0000244|PDB:2MDJ}.
FT   STRAND     2405   2409       {ECO:0000244|PDB:2MDC}.
FT   TURN       2410   2413       {ECO:0000244|PDB:2MDC}.
FT   STRAND     2414   2419       {ECO:0000244|PDB:2MDI}.
FT   STRAND     2424   2428       {ECO:0000244|PDB:2MDC}.
FT   HELIX      2463   2486       {ECO:0000244|PDB:2A7O}.
FT   TURN       2487   2489       {ECO:0000244|PDB:2A7O}.
FT   STRAND     2495   2498       {ECO:0000244|PDB:2A7O}.
FT   HELIX      2502   2524       {ECO:0000244|PDB:2A7O}.
FT   HELIX      2527   2529       {ECO:0000244|PDB:2A7O}.
FT   HELIX      2534   2548       {ECO:0000244|PDB:2A7O}.
FT   TURN       2549   2551       {ECO:0000244|PDB:2A7O}.
FT   HELIX      2557   2559       {ECO:0000244|PDB:2A7O}.
SQ   SEQUENCE   2564 AA;  287597 MW;  2B1BAE5867AB8EAB CRC64;
     MKQLQPQPPP KMGDFYDPEH PTPEEEENEA KIENVQKTGF IKGPMFKGVA SSRFLPKGTK
     TKVNLEEQGR QKVSFSFSLT KKTLQNRFLT ALGNEKQSDT PNPPAVPLQV DSTPKMKMEI
     GDTLSTAEES SPPKSRVELG KIHFKKHLLH VTSRPLLATT TAVASPPTHA APLPAVIAES
     TTVDSPPSSP PPPPPPAQAT TLSSPAPVTE PVALPHTPIT VLMAAPVPLP VDVAVRSLKE
     PPIIIVPESL EADTKQDTIS NSLEEHVTQI LNEQADISSK KEDSHIGKDE EIPDSSKISL
     SCKKTGSKKK SSQSEGIFLG SESDEDSVRT SSSQRSHDLK FSASIEKERD FKKSSAPLKS
     EDLGKPSRSK TDRDDKYFSY SKLERDTRYV SSRCRSERER RRSRSHSRSE RGSRTNLSYS
     RSERSHYYDS DRRYHRSSPY RERTRYSRPY TDNRARESSD SEEEYKKTYS RRTSSHSSSY
     RDLRTSSYSK SDRDCKTETS YLEMERRGKY SSKLERESKR TSENEAIKRC CSPPNELGFR
     RGSSYSKHDS SASRYKSTLS KPIPKSDKFK NSFCCTELNE EIKQSHSFSL QTPCSKGSEL
     RMINKNPERE KAGSPAPSNR LNDSPTLKKL DELPIFKSEF ITHDSHDSIK ELDSLSKVKN
     DQLRSFCPIE LNINGSPGAE SDLATFCTSK TDAVLMTSDD SVTGSELSPL VKACMLSSNG
     FQNISRCKEK DLDDTCMLHK KSESPFRETE PLVSPHQDKL MSMPVMTVDY SKTVVKEPVD
     TRVSCCKTKD SDIYCTLNDS NPSLCNSEAE NIEPSVMKIS SNSFMNVHLE SKPVICDSRN
     LTDHSKFACE EYKQSIGSTS SASVNHFDDL YQPIGSSGIA SSLQSLPPGI KVDSLTLLKC
     GENTSPVLDA VLKSKKSSEF LKHAGKETIV EVGSDLPDSG KGFASRENRR NNGLSGKCLQ
     EAQEEGNSIL PERRGRPEIS LDERGEGGHV HTSDDSEVVF SSCDLNLTME DSDGVTYALK
     CDSSGHAPEI VSTVHEDYSG SSESSNDESD SEDTDSDDSS IPRNRLQSVV VVPKNSTLPM
     EETSPCSSRS SQSYRHYSDH WEDERLESRR HLYEEKFESI ASKACPQTDK FFLHKGTEKN
     PEISFTQSSR KQIDNRLPEL SHPQSDGVDS TSHTDVKSDP LGHPNSEETV KAKIPSRQQE
     ELPIYSSDFE DVPNKSWQQT TFQNRPDSRL GKTELSFSSS CEIPHVDGLH SSEELRNLGW
     DFSQEKPSTT YQQPDSSYGA CGGHKYQQNA EQYGGTRDYW QGNGYWDPRS GRPPGTGVVY
     DRTQGQVPDS LTDDREEEEN WDQQDGSHFS DQSDKFLLSL QKDKGSVQAP EISSNSIKDT
     LAVNEKKDFS KNLEKNDIKD RGPLKKRRQE IESDSESDGE LQDRKKVRVE VEQGETSVPP
     GSALVGPSCV MDDFRDPQRW KECAKQGKMP CYFDLIEENV YLTERKKNKS HRDIKRMQCE
     CTPLSKDERA QGEIACGEDC LNRLLMIECS SRCPNGDYCS NRRFQRKQHA DVEVILTEKK
     GWGLRAAKDL PSNTFVLEYC GEVLDHKEFK ARVKEYARNK NIHYYFMALK NDEIIDATQK
     GNCSRFMNHS CEPNCETQKW TVNGQLRVGF FTTKLVPSGS ELTFDYQFQR YGKEAQKCFC
     GSANCRGYLG GENRVSIRAA GGKMKKERSR KKDSVDGELE ALMENGEGLS DKNQVLSLSR
     LMVRIETLEQ KLTCLELIQN THSQSCLKSF LERHGLSLLW IWMAELGDGR ESNQKLQEEI
     IKTLEHLPIP TKNMLEESKV LPIIQRWSQT KTAVPPLSEG DGYSSENTSR AHTPLNTPDP
     STKLSTEADT DTPKKLMFRR LKIISENSMD SAISDATSEL EGKDGKEDLD QLENVPVEEE
     EELQSQQLLP QQLPECKVDS ETNIEASKLP TSEPEADAEI EPKESNGTKL EEPINEETPS
     QDEEEGVSDV ESERSQEQPD KTVDISDLAT KLLDSWKDLK EVYRIPKKSQ TEKENTTTER
     GRDAVGFRDQ TPAPKTPNRS RERDPDKQTQ NKEKRKRRSS LSPPSSAYER GTKRPDDRYD
     TPTSKKKVRI KDRNKLSTEE RRKLFEQEVA QREAQKQQQQ MQNLGMTSPL PYDSLGYNAP
     HHPFAGYPPG YPMQAYVDPS NPNAGKVLLP TPSMDPVCSP APYDHAQPLV GHSTEPLSAP
     PPVPVVPHVA APVEVSSSQY VAQSDGVVHQ DSSVAVLPVP APGPVQGQNY SVWDSNQQSV
     SVQQQYSPAQ SQATIYYQGQ TCPTVYGVTS PYSQTTPPIV QSYAQPSLQY IQGQQIFTAH
     PQGVVVQPAA AVTTIVAPGQ PQPLQPSEMV VTNNLLDLPP PSPPKPKTIV LPPNWKTARD
     PEGKIYYYHV ITRQTQWDPP TWESPGDDAS LEHEAEMDLG TPTYDENPMK ASKKPKTAEA
     DTSSELAKKS KEVFRKEMSQ FIVQCLNPYR KPDCKVGRIT TTEDFKHLAR KLTHGVMNKE
     LKYCKNPEDL ECNENVKHKT KEYIKKYMQK FGAVYKPKED TELE
//
